Dados B3 › AGXY3 × RADL3 · Português
Each row uses the most recent year in which BOTH companies have the figure, and says which year that is. A cell with ! carries a caveat — hover to read it. We do not name a winner: that would be a recommendation, and this site does not give any.
| indicator | AGXY3 | RADL3 | year |
|---|---|---|---|
| ROE | -28.8% | 18.7% | 2023 |
| ROIC | -191.7%! | 22.4% | 2024 |
| ROA | -53.2% | 5.7% | 2024 |
| Gross margin | -1.3% | 29.7% | 2024 |
| EBIT margin | -42.8% | 6.1% | 2024 |
| Net margin | -65.5% | 3.1% | 2024 |
| Net debt/EBITDA | 2.56x | 0.72x | 2023 |
| Current ratio | 0.35x | 1.38x | 2024 |
| Revenue growth (1y) | -50.9% | 14.4% | 2024 |
| Revenue growth (5y CAGR) | 24.3% | 17.2% | 2024 |
| Piotroski F-Score | 2/9 | 7/9 | 2024 |
Priced at the first session on or after the day each filing became public — never the period close.
| indicator | AGXY3 | RADL3 | year |
|---|---|---|---|
| P/E | -0.76x | 32.24x | 2023 × 2025 |
| P/B | 0.26x | 5.71x | 2023 × 2025 |
| EV/EBITDA | 3.36x | 9.37x | 2023 × 2025 |
| FCF yield | -28.2% | 2.5% | 2023 × 2025 |
Numbers on this page are live. Data version 2026-09-01-supressao-declarada · page generated 2026-09-08 14:48 UTC. If this does not match /saude, you are reading a cached copy.
Home · Methodology · Transparency · Audit it